Agostina Nardone
Overview
Explore the profile of Agostina Nardone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
929
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scandino R, Nardone A, Casiraghi N, Galardi F, Genovese M, Romagnoli D, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):25.
PMID: 40057527
Cell-free DNA (cfDNA) extracted from peripheral blood has emerged as a crucial biomarker source in oncology research. To enhance the detection of somatic copy number alterations (SCNAs) and circulating tumor...
2.
Grinshpun A, Russo D, Ma W, Verma A, Hermida-Prado F, Sherman S, et al.
NPJ Breast Cancer
. 2024 Jun;
10(1):42.
PMID: 38851818
The ESR1 ligand binding domain activating mutations are the most prevalent genetic mechanism of acquired endocrine resistance in metastatic hormone receptor-positive breast cancer. These mutations confer endocrine resistance that remains...
3.
Migliaccio I, Romagnoli D, Galardi F, De Luca F, Biagioni C, Curigliano G, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300285.
PMID: 38427931
Purpose: To identify prognostic circulating biomarkers to cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), we performed a mutational analysis on circulating tumor DNA (ctDNA) samples from patients included in the...
4.
Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1889-1905.
PMID: 38381406
Purpose: Resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) is a clinical challenge in estrogen receptor (ER)-positive (ER+) breast cancer. Cyclin-dependent kinase 7 (CDK7) is a candidate target in...
5.
Cheng Y, Stein S, Nardone A, Liu W, Ma W, Cohen G, et al.
Cancer Res Commun
. 2023 Nov;
3(11):2331-2344.
PMID: 37921419
Significance: We created a computational modeling platform to predict the effects of fulvestrant/palbocilib treatment on WT-ER and Y537S-mutant breast cancer cells, and found that continuous treatment schedules are more effective...
6.
Fu X, Pereira R, Liu C, De Angelis C, Shea M, Nanda S, et al.
Cell Rep
. 2023 Jul;
42(8):112821.
PMID: 37467106
Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1)...
7.
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, et al.
Cancer Res
. 2023 Jul;
83(19):3284-3304.
PMID: 37450351
Significance: Adding SMAC mimetics to endocrine therapy enhances tumor regression in a cell autonomous manner while increasing tumor immunogenicity, indicating that this combination could be an effective treatment for HR+...
8.
Romagnoli D, Nardone A, Galardi F, Paoli M, De Luca F, Biagioni C, et al.
Brief Bioinform
. 2023 Jan;
24(2).
PMID: 36653909
DNA-methylation alterations are common in cancer and display unique characteristics that make them ideal markers for tumor quantification and classification. Here we present MIMESIS, a computational framework exploiting minimal DNA-methylation...
9.
Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, et al.
Clin Cancer Res
. 2022 Oct;
28(23):5066-5078.
PMID: 36215125
Purpose: Sensitivity to endocrine therapy (ET) is critical for the clinical benefit from the combination of palbociclib plus ET in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer. Bazedoxifene is a third-generation...
10.
Nardone A, Qiu X, Spisak S, Nagy Z, Feiglin A, Feit A, et al.
Cancer Res
. 2022 Aug;
82(20):3673-3686.
PMID: 35950920
Significance: A unique FOXA1-ER axis in invasive lobular breast cancer promotes disease progression and tamoxifen resistance, highlighting a potential therapeutic avenue for clinical investigations dedicated to this disease. See related...